SEATTLE and RICHMOND, BRITISH COLUMBIA - Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement. This agreement covers Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies, enabling SignalChem Biotech to incorporate these technologies into custom luminescent assay development and protein-fusion services for third-party customers in research settings.
The collaboration is a strategic move for Sino Biological, which aims to integrate AI-enabled technologies across its global life science tools and services portfolio. Dr. Rob Burgess, Chief Business Officer of Sino Biological, emphasized the significance of this partnership: "By incorporating Monod Bio's AI-designed protein technologies into SignalChem's custom assay platform, we can help researchers obtain high quality discovery candidates more rapidly. This agreement and the corresponding licensed technology strengthen our ability to help customers address complex biological questions and advance their research programs more efficiently."
Monod Bio's LuxSit is an AI-designed luciferase engineered for use in robust luminescent biosensors, while its NovoBodies are compact, highly stable binding proteins designed for high-performance recognition of various targets. Together, these technologies provide versatile tools for developing customized assays and discovery workflows, which are critical for accelerating research in drug discovery and life sciences.
Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio, expressed enthusiasm about the partnership: "SignalChem Biotech and Sino Biological have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base. This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services."
The licensing agreement marks a notable development in the application of AI-designed proteins in the life sciences industry. By leveraging Monod Bio's innovative technologies, SignalChem Biotech can enhance its custom assay services, offering researchers more efficient and effective tools for their studies. This partnership underscores the growing trend of incorporating AI into protein design and its potential to transform research capabilities.
SignalChem Biotech, as a wholly-owned subsidiary of Sino Biological, provides specialized reagents and CRO services supporting drug discovery and life science research. Sino Biological is an international life science tools provider with facilities across Asia, North America and Europe. For more information, visit www.sinobiological.com.
Monod Bio uses AI-powered de novo protein design to create novel binders, biosensors and other functional proteins for research and diagnostic applications. Through its Monod Inside model, Monod Bio partners with life science companies to integrate its technologies into next-generation products and services. For more information, visit monod.bio.
